Sector
PharmaceuticalsOpen
₹3,404Prev. Close
₹3,404.9Turnover(Lac.)
₹16,993.89Day's High
₹3,451.7Day's Low
₹3,376.452 Week's High
₹3,590.752 Week's Low
₹2,870Book Value
₹224.34Face Value
₹5Mkt Cap (₹ Cr.)
1,16,406.47P/E
60.94EPS
55.91Divi. Yield
0.1825 Jun 2024
12:00 AM
AGM
Announcement Date: 25 Jun, 2024
29 Jun 2025
12:00 AM
Board Meeting
Agenda : Audited Result
The transaction involves around 38.75 lakh shares, priced at ₹1,600 each, being offloaded by JB Chemicals employees who recently converted their stock options.
The acquisition values JB Chemicals at ₹25,689 crore on a fully diluted basis, according to the company’s official announcement.
On the operating front, EBITDA for the quarter was reported at ₹964 Crore. It was 9.20% higher than ₹883 in Q4FY24.
Here are some of the stocks that may see significant price movement today: JK Cement, KEC International, Macrotech Developers, etc.
Empagliflozin is a new sodium-glucose co-transporter-2 (SGLT-2) inhibitor approved for glycemic management in individuals with type 2 diabetes.
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 169.23 | 169.23 | 169.23 | 84.62 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 7,423.27 | 6,659.53 | 6,286.73 | 6,260.8 |
Net Worth | 7,592.5 | 6,828.76 | 6,455.96 | 6,345.42 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 6,742.32 | 6,450.57 | 6,168.44 | 4,248.24 |
yoy growth (%) | 4.52 | 4.57 | 45.19 | -7.49 |
Raw materials | -1,907.5 | -1,669.67 | -1,637.45 | -1,115.69 |
As % of sales | 28.29 | 25.88 | 26.54 | 26.26 |
Employee costs | -1,097.93 | -1,097.12 | -1,061.76 | -826.07 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 1,466.21 | 1,366.11 | 1,116.77 | 562.13 |
Depreciation | -602.43 | -609.84 | -606.66 | -383.88 |
Tax paid | -474.76 | -228.26 | -178.26 | -80.09 |
Working capital | -48.68 | 274.86 | 692.18 | 68.94 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 4.52 | 4.57 | 45.19 | -7.49 |
Op profit growth | -4.15 | 14.33 | 111.26 | -19.49 |
EBIT growth | 0.13 | 9.88 | 80.79 | -26.05 |
Net profit growth | -12.86 | 21.24 | 94.69 | -43.56 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 11,317 | 10,562 | 9,464 | 8,419 | 7,886 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 11,317 | 10,562 | 9,464 | 8,419 | 7,886 |
Other Operating Income | 199 | 166 | 156 | 89 | 119 |
Other Income | 23 | 146 | 45 | 197 | 57 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,682.6 | 94.39 | 4,03,580.14 | 2,000.46 | 0.95 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,778.5 | 81.52 | 1,80,068.67 | 667 | 0.44 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,484 | 24.91 | 1,19,918.75 | 1,485.4 | 1.08 | 4,254.47 | 397.39 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,404.9 | 60.94 | 1,15,304.87 | 474 | 0.18 | 2,385 | 224.34 |
Mankind Pharma Ltd MANKIND | 2,696.5 | 59.14 | 1,11,428.51 | 382.46 | 0 | 2,126.59 | 354.71 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Chairman
Samir Mehta
Independent Director
Ameera Shah
Independent Director
Nayantara Bali
Whole Time Director
Aman Mehta
Independent Director
Manish Choksi
Company Sec. & Compli. Officer
Chintan Trivedi
Independent Director
Nikhil Khattau
Non Executive Director
Jindal Mehta
Torrent House,
Off Ashram Road,
Gujarat - 380009
Tel: 91-79-26599000
Website: http://www.torrentpharma.com
Email: investorservices@torrentpharma.com
Karvy Selenium Tow-B,
31&32 Financial Dist, Nanakramguda,
Hyderabad-500032
Tel: 91-40-67162222
Website: www.kfintech.com
Email: einward.ris@kfintech.com
Summary
Torrent Pharmaceuticals Limited is a leading player in the Indian pharmaceutical sector, concentrating on the chronic and sub-chronic therapeutic segments. The Company has established itself as a lead...
Read More
Reports by Torrent Pharmaceuticals Ltd
What is the Torrent Pharmaceuticals Ltd share price today?
What is the Market Cap of Torrent Pharmaceuticals Ltd?
What is the PE and PB ratio of Torrent Pharmaceuticals Ltd?
What is the 52 Week High and Low of Torrent Pharmaceuticals Ltd?
What is the CAGR of Torrent Pharmaceuticals Ltd?
What is the shareholding pattern of Torrent Pharmaceuticals Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
